Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in

Prof. Andrew Beggs

Andrew Beggs

Andrew Beggs is a Professor of Cancer Genetics & Surgery in the Institute of Cancer and Genomic Sciences, University of Birmingham. He is also the Deputy Director of the Birmingham Experimental Cancer Medicine Centre and Theme Lead for Biomarkers and Liquid Biopsy.  He also is Head of Somatic Cancer in the Central and South Genomic Medicine Service Alliance. He is Co-Lead of the Translational Biology and Genetics research theme within the Institute of Cancer and Genomic Sciences. He is a fellow of the Alan Turing Institute and has recently been awarded an MRC Senior Clinical Fellowship.

print
PRINT

Featured content

Next-generation sequencing

Oncology Podcast

Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this podcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company

Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs

NSCLC Expert Interview

Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this vodcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint. 

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Image Credits